First-in-class small molecule modulators of the IL-6–gp130 axis
Validated Pathway
The IL-6/gp130 signaling axis is a major contributor to chronic inflammation.
Redefining Inflammation
Innata Bio designs first‑in‑class small molecules that fine‑tune IL‑6/gp130 signaling—reducing harmful inflammation without shutting down the pathways essential for tissue repair and immune balance.
Differentiated Mechanism
First-in-class small molecules modulate IL-6/gp130 signaling: fine-tuning, not inhibiting.
Unlocking Precision
Modulation enables beneficial signaling downstream of gp130 that inhibition blocks.
Improving Tolerability
Optimizing signaling downstream of the IL-6/gp130 axis reduces inflammation without compromising innate immune functions
Broad Therapeutic Potential
We focus on inflammatory diseases with high unmet need: osteoarthritis, idiopathic pulmonary fibrosis and cardiometabolic disorders.
Fundamental Advance in Understanding Inflammation
- Featured on the cover of Science Translational Medicine in March 2023
- Dose-dependent reduction in pain and improvement in cartilage regeneration
- Final data will be presented at OARSI World Congress on Osteoarthritis in April 2026
Research in Partnership with
